Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 10/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | NFKBIA | P25963 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | RELA | Q04206 | 4/20 | 1.00 |
| ▸ | GLO1 | Q04760 | 6/20 | 0.64 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.59 |
| ▸ | G6PD | P11413 | 1/20 | 0.59 |
| ▸ | METAP2 | P50579 | 1/20 | 0.59 |
| ▸ | METAP1 | P53582 | 1/20 | 0.59 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | MITF | O75030 | 1/20 | 0.55 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13633877 | 0.84 | NFKBIA (1.00) | SLC40A1TDP1KMT2ANFKBIAMEN1 | |
| SCHEMBL18910581 | 0.82 | NFKBIA (1.00) | SLC40A1TDP1KMT2ANFKBIAMEN1 | |
| SCHEMBL13633764 | 0.81 | MEN1 (0.71) | SLC40A1TDP1KMT2ANFKBIAMEN1 | |
| SCHEMBL13633824 | 0.81 | SLC40A1 (0.68) | SLC40A1TDP1KMT2ANFKBIAMEN1 | |
| SCHEMBL13633913 | 0.81 | SLC40A1 (0.68) | SLC40A1TDP1KMT2ANFKBIAMEN1 | |
| SCHEMBL13633769 | 0.81 | SLC40A1 (0.70) | SLC40A1TDP1KMT2ANFKBIAMEN1 | |
| SCHEMBL15508514 | 0.80 | SLC40A1 (0.67) | SLC40A1TDP1KMT2ANFKBIAMEN1 | |
| SCHEMBL7190921 | 0.78 | GLO1 (1.00) | SLC40A1TDP1KMT2ANFKBIAMEN1 | |
| SCHEMBL11973892 | 0.78 | THRB (0.65) | SLC40A1TDP1KMT2ANFKBIAMEN1 | |
| SCHEMBL13633882 | 0.77 | SLC40A1 (0.63) | SLC40A1TDP1KMT2ANFKBIAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | SLC40A1 2/4885TDP1 4862/4885KMT2A 3298/4885 |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | SLC40A1 2/4885TDP1 4862/4885KMT2A 3298/4885 |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PDE4B, PDE7B, PDE4A | SLC40A1 4638/4885TDP1 83/4885KMT2A 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.